title: Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome.
abstract: OBJECTIVE
  To assess the long-term neurodevelopment of children exposed in utero to selective serotonin reuptake inhibitors (SSRIs) that developed a neonatal abstinence syndrome (NAS).
  
  
  METHODS
  Neurodevelopmental evaluation was performed at the age of 2 to 6 years. Children who developed NAS were compared with those who did not using univariate and logistic regression analyses.
  
  
  RESULTS
  Thirty children with NAS and 52 without NAS participated in the study. Both groups were similar in mean cognitive ability (106.9±14.0 vs 100.5±14.6, P=0.12) and developmental scores (98.9±11.4 vs 95.7±9.9, P=0.21). However, there was a trend towards small head circumference in the NAS group (20 vs 6%, P=0.068). NAS was associated with an increased risk of social-behavior abnormalities (odds ratio (OR) 3.03, 95% confidence interval (CI) 1.07 to 8.60, P=0.04) and advanced maternal age (OR 1.12, 95% CI 1.00 to 1.25, P=0.04).
  
  
  CONCLUSIONS
  Infants who developed NAS had normal cognitive ability, but were at an increased risk for social-behavioral abnormalities. Follow-up evaluation of symptomatic neonates should be considered.
authors.affiliation: Neonatal Intensive Care Unit, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel. gilkl@post.tau.ac.il
authors.forename: G
authors.initials: G
authors.lastname: Klinger
authors.forename: D
authors.initials: D
authors.lastname: Frankenthal
authors.forename: P
authors.initials: P
authors.lastname: Merlob
authors.forename: G
authors.initials: G
authors.lastname: Diamond
authors.forename: L
authors.initials: L
authors.lastname: Sirota
authors.forename: R
authors.initials: R
authors.lastname: Levinson-Castiel
authors.forename: N
authors.initials: N
authors.lastname: Linder
authors.forename: B
authors.initials: B
authors.lastname: Stahl
authors.forename: D
authors.initials: D
authors.lastname: Inbar
mesh_terms: D000328:Adult; D002648:Child; D002657:Child Development / Q000187:drug effects; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced / Q000175:diagnosis; D009357:Neonatal Abstinence Syndrome / Q000209:etiology / Q000523:psychology*; D009483:Neuropsychological Tests; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011446:Prospective Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors